Natixis Investment Managers International Alnylam Pharmaceuticals, Inc. Transaction History

Natixis Investment Managers International

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$62.67 - $88.33 $334,219 - $471,063	-5,333 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$87.52 - $122.67 $337,827 - $473,506	-3,860 Reduced 41.99%	5,333 $467,000
Q2 2018 Aug 14, 2018	BUY	$88.31 - $107.8 $59,520 - $72,657	674 Added 7.91%	9,193 $905,000
Q1 2018 May 15, 2018	BUY	$115.92 - $148.54 $437,829 - $561,035	3,777 Added 79.65%	8,519 $1.02 Million
Q4 2017 Feb 14, 2018	SELL	$114.49 - $139.98 $278,783 - $340,851	-2,435 Reduced 33.93%	4,742 $602,000
Q3 2017 Nov 14, 2017	SELL	$72.53 - $118.27 $572,624 - $933,741	-7,895 Reduced 52.38%	7,177 $843,000
Q2 2017 Aug 14, 2017	BUY	N/A	15,072	15,072 $1.2 Million

720

111M

978K

881K

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $38.5B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Natixis Investment Managers International, based on Form 13F filings with the SEC.

Stay updated on Natixis Investment Managers International with notifications on news.